-

Dr. Saud A. Sadiq Featured in CNN Article

Piece highlights how the Tisch Multiple Sclerosis Research Center of New York has been able to support Jamie-Lynn Sigler, one of its patients, in treating her MS

NEW YORK--(BUSINESS WIRE)--The Tisch Multiple Sclerosis Research Center of New York, the world’s largest independent research center focusing on MS, is proud to announce that its Director and Chief Research Scientist, Dr. Saud A. Sadiq, was featured in a recent article in CNN.

The CNN piece profiles one of the center’s patients, actress Jamie-Lynn Sigler. It describes how Jamie-Lynn has been able to navigate her MS journey, alongside her career and motherhood, in part due to the support and care provided to her by Dr. Sadiq and the Tisch team. The article also details how Dr. Sadiq was able to offer guidance and reassurance to Jamie-Lynn in managing her MS through the COVID-19 pandemic.

“We’re proud to have Jamie-Lynn as one of our patients and to support her on her MS journey,” Dr. Sadiq said. “We’re so grateful to have Jamie-Lynn – as well as our other patients and donors – as advocates of the great work our team is doing. Due to their support, we are able to ensure positive treatment outcomes for patients, as well as in conduct cutting-edge research to find the cause and ultimately, the cure for MS.”

The full CNN article can be accessed here.

About the Tisch MS Research Center of New York

The mission of the Tisch Multiple Sclerosis Research Center of New York is to conduct groundbreaking medical research to ensure unparalleled care and positive outcomes for MS patients. Its integrated relationship with the International Multiple Sclerosis Management Practice (IMSMP) accelerates the pace at which research discoveries translate from lab bench to bedside. The Center aims to identify the cause of MS, understand disease mechanisms, optimize therapies, and repair the damage caused by MS while offering patients access to the best and most advanced treatments possible.

Contacts

Kerry Close
kclose@groupgordon.com

Industry:

Tisch Multiple Sclerosis Research Center of New York

Release Summary
The Tisch Multiple Sclerosis Research Center of New York is proud to announce that Dr. Saud A. Sadiq was featured in a recent article in CNN.
Release Versions
English

Contacts

Kerry Close
kclose@groupgordon.com

More News From Tisch Multiple Sclerosis Research Center of New York

First FDA-Approved Phase II Stem Cell Treatment Study Shows Significant Improvements in Progressive MS Patients

NEW YORK--(BUSINESS WIRE)--The Tisch MS Research Center of New York, the world’s largest MS research center, has announced publication of the results of its FDA-approved Phase II stem cell treatment study in a leading stem cell journal, Stem Cell Research & Therapy. The study, which focused on Progressive MS patients, did not meet its primary endpoint but showed improvements in multiple areas – including walking speed, bladder function, and gray matter volume – for patients with significant...

FDA-Approved Phase II Stem Cell Treatment Trial Shows Significant and Diverse Improvements for Multiple Sclerosis (MS) Patients

NEW YORK--(BUSINESS WIRE)--The Tisch MS Research Center of New York, the world’s largest independent research center focused on MS, today announced the Phase II results of its FDA-approved stem cell treatment study. The research is a continuation of a Phase I trial, which was the first ever in the U.S. to receive FDA approval to investigate the injection of stem cells into the cerebrospinal fluid of MS patients. The Phase II trial showed improvements across multiple areas in progressive MS pati...

New Study Reveals New Potential Therapeutic Target for Experimental Multiple Sclerosis Treatment

NEW YORK--(BUSINESS WIRE)--The Tisch MS Research Center of New York (MSRCNY), the world’s largest independent research center focused on multiple sclerosis, has published new research finding that microglia could be a potential therapeutic target for mesenchymal stem cell-derived neural progenitor cell (MSC-NP) therapy, an experimental approach to treating multiple sclerosis. This treatment approach uses bone marrow cells (MSC-NPs) that are injected into the spinal fluid of the patient, aiming...
Back to Newsroom